Skip to content

PEP-device for Treatment of Swimming-induced Pulmonary Edema (SIPE)

Evaluation of Positive Expiratory Pressure Device (PEP-device) for Treatment of Swimming Induced Pulmonary Edema (SIPE) - a Randomized Single-blinded Controlled Study

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05227222
Enrollment
40
Registered
2022-02-07
Start date
2022-07-02
Completion date
2027-07-15
Last updated
2025-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Diseases, Pulmonary Edema, Swimming Induced Pulmonary Edema (SIPE)

Keywords

positive expiratory pressure, therapeutics, ultrasonography, oximetry

Brief summary

In swimming induced pulmonary edema (SIPE), there is a lack of knowledge regarding optimal treatment. The present study was designed to assess the benefit of treatment with positive expiratory pressure device (PEP-device) compared to spontaneous recovery in patients with SIPE without hypoxia in the out-of-hospital environment.

Detailed description

Swimming induced pulmonary edema (SIPE) is an unusual condition affecting otherwise healthy swimmers. SIPE is characterized by acute onset of dyspnea and cough, excessive sputum and occasionally hemoptysis when swimming in open water. The condition usually resolves spontaneously within 48 hours, but may result in serious illness and require emergency care. Case reports describe acute treatment with or without oxygen in combination with diuretics, beta-agonist-inhalation or continuous positive airway pressure (CPAP). Evidence for optimal treatment strategy is lacking. Oxygen treatment might not be appropriate for patients with SIPE presenting without hypoxia. It is unknown if positive airway pressure accelerates recovery in SIPE. This study intends to determine whether treatment with positive expiratory pressure (PEP) applied by PEP-device accelerates increase of oxygen saturation compared to spontaneous recovery in patients presenting with SIPE without hypoxia. The aim is to treat patients on site without involving hospital care. We study a large cohort of approximately 12 000 swimmers during Vansbrosimningen, Sweden's biggest annual open water event with a yearly incidence of SIPE about 0,4%. Adult patients clinically diagnosed with SIPE and oxygen saturation ≥92% are randomly assigned to 2 groups: (1) PEP-device for 20 minutes or (2) control group with spontaneous recovery without active treatment for 20 minutes. Assessment with outcome measures is taken 10 minutes after intervention/control. Primary endpoint: oxygen saturation (%) by pulse oxymetry.

Interventions

DEVICEPEP-device

PEP-device

Sponsors

Dalarna County Council, Sweden
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* clinical diagnosis of swimming induced pulmonary edema (SIPE) with need of acute treatment * peripheral oxygen saturation ≥92% * 18 years or older * informed consent

Exclusion criteria

* declined consent * suspected acute coronary syndrome * severe asthma diagnosed together with pulmonary edema with requirement of beta-agonist-inhalation prior to treatment of pulmonary edema * hemodynamic instability or decreased consciousness

Design outcomes

Primary

MeasureTime frameDescription
Absolute peripheral oxygen saturation (%) after treatmentafter 20 min treatment followed by 10 min restPeripheral oxygen saturation % (continuous variable) measured by peripheral pulse oximetry

Secondary

MeasureTime frameDescription
Recovery (yes/no) after treatmentafter 20 min treatment followed by 10 min restRecovery, defined by peripheral oxygen saturation \>95% after treatment or no recovery, defined by peripheral oxygen saturation ≤95% after treatment
Interstitial syndrome assessed by lung ultrasound (yes/no) after treatmentafter 20 min treatment followed by 10 min restFour chest regions for both lungs are scanned by lung ultrasound; a positive region defined by the presence of three or more B-line artifacts. Bilateral or unilateral presence of two or more positive regions define positive interstitial syndrome
Absolute number of regions presenting B-lines on lung ultrasound after treatmentafter 20 min treatment followed by 10 min restFour chest regions for both lungs are scanned by lung ultrasound; a positive region defined by the presence of three or more B-line artifacts. Assessment of the total number of positive regions.
Change in absolute peripheral oxygen saturation (%) before and after treatmentchange before versus after 20 min treatment followed by 10 min restChange in peripheral oxygen saturation % (continuous variable) measured by pulse oximetry before and after treatment
Change in patient reported outcome measures before and after treatmentchange before versus after 20 min treatment followed by 10 min restSix different patient reported outcome measures assessed by numerical rating scale (NRS; min-max 0-10): cough, sputum, air hunger, breathing effort, tightness in chest, anxiousness. The patients will assess symptoms prior to and after treatment
Admission to hospital (yes/no)1 hourAdmission to hospital within or after a maximal treatment time of 1 hour
Total treatment time1 hourTotal treatment time until oxygen saturation ≥96% is reached
Change in absolute number of regions presenting B-lines on lung ultrasound before and after treatmentchange before versus after 20 min treatment followed by 10 min restFour chest regions for both lungs are scanned by lung ultrasound; a positive region defined by the presence of three or more B-line artifacts. Assessment of the total number of positive regions. Change in absolute number of regions presenting B-lines on lung ultrasound before and after treatment

Countries

Sweden

Contacts

Primary ContactMaria Hårdstedt, MD/PhD
maria.hardstedt@regiondalarna.se46-738089464

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026